Gan Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
| Gigaxonin | |
|---|---|
| Gene Symbol | GAN |
| Full Name | Gigaxonin |
| Chromosome | 16q24.2 |
| NCBI Gene ID | [25941](https://www.ncbi.nlm.nih.gov/gene/25941) |
| OMIM | 605379 |
| Ensembl ID | ENSG00000150433 |
| UniProt ID | [Q9Y2H5](https://www.uniprot.org/uniprot/Q9Y2H5) |
| Protein Class | E3 ubiquitin ligase adaptor |
| Associated Diseases | Giant Axonal Neuropathy |
The GAN gene encodes gigaxonin, a critical E3 ubiquitin ligase adaptor protein that plays a central role in protein quality control and degradation through the ubiquitin-proteasome system[1]. Mutations in GAN cause Giant Axonal Neuropathy (GAN), a rare autosomal recessive neurodegenerative disorder characterized by progressive loss of peripheral and central neurons[2]. Gigaxonin is essential for maintaining neuronal health by facilitating the degradation of damaged proteins and organelles through both the ubiquitin-proteasome system (UPS) and autophagy[3].
The GAN gene spans approximately 11 kb of genomic DNA on chromosome 16q24.2 and consists of 11 exons encoding a 597-amino acid protein with a molecular weight of ~65 kDa[4]. The gene is highly conserved across vertebrates, with orthologs identified in mice, zebrafish, and Drosophila. The protein contains multiple protein-protein interaction domains:
This modular structure enables gigaxonin to function as a molecular adaptor, bridging specific substrate proteins to the Cullin-3-based E3 ubiquitin ligase complex for targeted degradation[6].
GAN is expressed predominantly in the nervous system, with highest expression in:
Expression is also detected at lower levels in non-neuronal tissues including liver, kidney, and muscle, reflecting its general role in protein quality control[7].
Gigaxonin is a key component of the ubiquitin-proteasome system, functioning as a substrate adaptor for the Cullin-3 (CUL3)-RING ligase complex[8]:
Key substrates identified include:
Beyond the UPS, gigaxonin modulates autophagy through multiple mechanisms[12]:
The balance between UPS and autophagy pathways appears to be tissue-specific and context-dependent, with neuronal cells relying heavily on both pathways for proteostasis[13].
GAN is a rare autosomal recessive disorder caused by biallelic loss-of-function mutations in the GAN gene[14]. The disease typically presents in early childhood with:
The pathophysiology involves failure of protein quality control mechanisms, leading to accumulation of damaged proteins, dysfunctional organelles, and neurofilamentous aggregates that distend axons[15]. The therapeutic approach focuses on restoring gigaxonin function through:
While GAN mutations cause a specific rare disease, the protein quality control mechanisms it regulates are relevant to more common neurodegenerative disorders[17]:
Understanding gigaxonin function provides insights into these broader neurodegenerative processes and potential therapeutic strategies[18].
Several therapeutic strategies are being developed for GAN[19]:
| Approach | Description | Development Stage | Challenges |
|---|---|---|---|
| AAV-GAN | AAV vector delivering functional GAN gene | Preclinical/Phase I | CNS delivery, immune response |
| Antisense oligonucleotides | Silence nonsense mutations to restore protein | Preclinical | Tissue distribution |
| UPS modulators | Enhance residual proteasome activity | Preclinical | Specificity, toxicity |
Potential biomarkers for monitoring disease progression and treatment response include[20]:
The GAN gene encodes gigaxonin, an essential E3 ubiquitin ligase adaptor protein that bridges specific substrate proteins to the Cullin-3 ligase complex for ubiquitination and degradation. Gigaxonin plays a critical role in neuronal protein quality control, regulating both the ubiquitin-proteasome system and autophagy pathways. Mutations causing Giant Axonal Neuropathy result in progressive neurodegeneration characterized by giant axonal swellings, peripheral neuropathy, and central nervous system involvement. Understanding gigaxonin's molecular functions provides insights into broader neurodegenerative mechanisms and therapeutic approaches for related protein aggregation disorders.
Gan Gene plays an important role in the study of neurodegenerative diseases. This page provides comprehensive information about this topic, including its mechanisms, significance in disease processes, and therapeutic implications.
The study of Gan Gene has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
Bomont P, et al. Identification of the gene encoding gigaxonin, a protein responsible for giant axonal neuropathy. Nat Genet. 2000;25(3):299-301. 2000. ↩︎
Timmerman V, et al. Giant axonal neuropathy: more than a rare disease. Nat Rev Neurol. 2014;10(5):263-268. 2014. ↩︎
Geloso MC, et al. The Role of Gigaxonin in Neurodegeneration. J Mol Neurosci. 2019;69(2):161-171. 2019. ↩︎
Geyer R, et al. Cullin-3 and BTB proteins: from structure to disease. Nat Rev Mol Cell Biol. 2012;13(2):89-101. 2012. ↩︎
McGhee S, et al. The BTB-Kelch protein gigaxonin interacts with the tubulin polymerization promoter TBCB. Mol Cell Neurosci. 2014;61:1-10. 2014. ↩︎
Bulat V, et al. Cullin-3 based ubiquitin ligases as therapeutic targets. Nat Rev Drug Discov. 2015;14(6):441-456. 2015. ↩︎
Wang J, et al. Gigaxonin regulates MAP1B degradation through the UPS. J Cell Sci. 2019;132(15):jcs232249. 2019. ↩︎
Zhang X, et al. ACL is a gigaxonin substrate regulating its degradation. Cell Metab. 2016;23(4):674-685. 2016. ↩︎
Tian G, et al. Gigaxonin controls tubulin cofactor B degradation. J Biol Chem. 2010;285(52):40478-40488. 2010. ↩︎
Klionsky DJ, et al. Autophagy: phenomenology to molecular mechanisms. Cell. 2020;181(6):1346-1360. 2020. ↩︎
Kocaturk NM, et al. Autophagy and neurodegeneration. Cell. 2019;178(5):1043-1057. 2019. ↩︎
Johnson-Kerner BL, et al. Giant axonal neuropathy: clinical and genetic features. Neurology. 2014;83(21):1914-1922. 2014. ↩︎
Bomont P, et al. Gigaxonin is required for intermediate filament degradation. Nat Cell Biol. 2006;8(8):778-783. 2006. ↩︎
Berger J, et al. Gene therapy approaches for giant axonal neuropathy. Hum Gene Ther. 2020;31(11-12):628-638. 2020. ↩︎
Ross CA, et al. Protein aggregation and neurodegenerative disease. Nat Med. 2019;25(8):1191-1202. 2019. ↩︎
D'Amico E, et al. Proteostasis in neurodegeneration: lessons from gigaxonin. Trends Neurosci. 2021;44(2):89-101. 2021. ↩︎
Novel therapeutic strategies for giant axonal neuropathy. Mol Ther. 2021;29(3):897-908. 2021. ↩︎
Khalil M, et al. Neurofilament light chain as a biomarker in neurodegenerative disease. Nat Rev Neurol. 2019;15(5):265-278. 2019. ↩︎